NTLA Intellia Therapeutics, Inc.

NASDAQ
$12.14

Intellia Therapeutics, Inc. (NTLA) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

30D 90D 6M 1Y
Insider signal In line Selling ran in line with NTLA's own trailing one-year pace, with 56% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 3 sellers in the last 90 days
Insiders buying
1
1 transaction
Insiders selling
7
19 transactions
Purchases
$1.4M
150,000 shares
Sales
$2.2M
213,807 shares
Net activity
-$770.7K
purchases less sales

How much of that selling was preplanned? 56% planned / 44% discretionary

10b5-1 plan sales $1.2M 6 transactions · 115,498 shares
Discretionary sales $965.8K 13 transactions · 98,309 shares

Largest single sale: $474.1K.

Where they traded

Buy Sell Dot area is proportional to transaction value.

Last open-market purchase: January 5, 2026 , by Cohen Fred E .

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
LEONARD JOHN M President and CEO Sell 10b5-1 2,785 $13.00 $36.2K 1,147,064 −0.2% of holding
LEONARD JOHN M President and CEO Sell 10b5-1 19,890 $12.60 $250.6K 1,149,849 −1.7% of holding
Dulac Edward J III EVP, Chief Financial Officer Sell 8,111 $11.25 $91.2K 148,175 −5.2% of holding
Dulac Edward J III EVP, Chief Financial Officer Sell 10b5-1 4,677 $18.00 $84.2K 156,286 −2.9% of holding
Dube Michael P VP, Chief Accounting Officer Sell 2,641 $16.78 $44.3K 66,886 −3.8% of holding
BASTA JAMES EVP, General Counsel Sell 1,211 $13.78 $16.7K 156,794 −0.8% of holding
Clark Eliana EVP, Chief Technical Officer Sell 607 $13.78 $8.4K 93,864 −0.6% of holding
Cohen Fred E Director Buy 150,000 $9.35 $1.4M 207,453
LEONARD JOHN M President and CEO Sell 34,146 $9.21 $314.5K 1,013,339 −3.3% of holding
Lebwohl David EVP, Chief Medical Officer Sell 11,903 $9.21 $109.6K 121,249 −8.9% of holding
BASTA JAMES EVP, General Counsel Sell 10,397 $9.21 $95.8K 101,528 −9.3% of holding
Clark Eliana EVP, Chief Technical Officer Sell 9,515 $9.21 $87.6K 87,118 −9.8% of holding
Schultes Birgit C EVP, Chief Scientific Officer Sell 8,508 $9.21 $78.4K 98,533 −7.9% of holding
Dulac Edward J III EVP, Chief Financial Officer Sell 6,379 $9.21 $58.8K 99,683 −6% of holding
Dube Michael P VP, Chief Accounting Officer Sell 2,989 $9.21 $27.5K 52,277 −5.4% of holding
LEONARD JOHN M 3 fills President and CEO Sell 10b5-1 88,146 $9.49 $836.4K 1,077,115 −7.6% of holding
Dube Michael P VP, Chief Accounting Officer Sell 1,871 $17.38 $32.5K 55,266 −3.3% of holding
Schultes Birgit C EVP, Chief Scientific Officer Sell 31 $17.38 $539 105,184 −0% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.